Sign in Subscribe
Pharmaceutical industry

Sales of Herceptin to Nearly Triple by 2015

Strategic Insights

— 1 min read

Sales of Genentech/Roche/Chugai's Herceptin (trastuzumab) are expected to reach $3.3 billion in 2015, nearly tripling its current sales. The growth is driven by the expansion of established agents, particularly Herceptin, into the adjuvant setting, which offers a larger patient pool and longer duration of therapy. This trend, coupled with the launch of new agents like GlaxoSmithKline's Tykerb (lapatinib) and Genentech/Roche/Chugai's Avastin (bevacizumab), will bolster the breast cancer market during the 2010-2015 time frame, despite patent expiries limiting overall annual market growth.

Key Takeaways:

  • Sales of Herceptin are expected to reach $3.3 billion in 2015, with growth driven by its expansion into the adjuvant setting.
  • The chemotherapy market in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan will be bolstered by the use of new drugs, including Tykerb (lapatinib) and Avastin (bevacizumab).
  • The value of the adjuvant market is higher than that of the metastatic market due to a larger patient pool and longer duration of therapy.
  • Decision Resources, Inc. forecasts that new agents, particularly Tykerb and Avastin, will help to bolster the market during the 2010-2015 time frame, despite patent expiries limiting overall annual market growth.
  • Breast cancer is the most common cancer in women worldwide, with more than 2 million prevalent cases in the major markets.
  • Advances in screening and treatment have improved survival rates for women with breast cancer.
  • Mary Argent-Katwala, Ph.D., analyst at Decision Resources, Inc., cites the importance of market research and advisory services in providing insights into the pharmaceutical and healthcare industries.

Statistics:

  • Sales of Herceptin are expected to reach $3.3 billion in 2015.
  • The breast cancer market is expected to grow due to the expansion of established agents, particularly Herceptin, into the adjuvant setting.
  • The chemotherapy market in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan will be bolstered by the use of new drugs, including Tykerb (lapatinib) and Avastin (bevacizumab).
  • The adjuvant market is expected to grow at a higher rate than the metastatic market due to a larger patient pool and longer duration of therapy.
  • Breast cancer is the most common cancer in women worldwide, with more than 2 million prevalent cases in the major markets.
  • Advances in screening and treatment have improved survival rates for women with breast cancer by an unspecified percentage.

Sources:

  • Decision Resources, Inc.
  • Health & Medicine Week
  • NewsRx.com

Read more